Anaptys To Receive $50M Upfront Cash Payment From Sagard Healthcare From Amended Agreement In Exchange For Additional Jemperli Royalties
Portfolio Pulse from Benzinga Newsdesk
AnaptysBio, Inc. (NASDAQ:ANAB) has amended its agreement with Sagard Healthcare, receiving a $50 million upfront cash payment in exchange for additional Jemperli royalties. The agreement now extends until Sagard achieves a capped payoff, with the terms set at $600 million by March 31, 2031, or $675 million if received thereafter. AnaptysBio plans to use the proceeds to further develop its immune cell modulators, including checkpoint agonists for autoimmune and inflammatory diseases.
May 09, 2024 | 9:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AnaptysBio, Inc. receives a $50 million upfront payment from Sagard Healthcare for additional Jemperli royalties, with plans to invest in the development of immune cell modulators.
The $50 million upfront payment from Sagard Healthcare represents a significant financial infusion for AnaptysBio, Inc., likely to positively impact its stock price in the short term. This capital injection enables the company to accelerate the development of its immune cell modulators, potentially enhancing its product pipeline and future revenue prospects. Given the direct financial benefit and strategic importance of this deal for AnaptysBio's growth and development strategy, it is expected to be viewed positively by investors.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100